Antitumor effect of locally produced CD95 ligand

Nature Medicine

Volumn 3, Issue 2, 1997, Pages 165-170

  Seino, Ken Ichiro ^a,b   Kayagaki, Nobuhiko ^a   Okumura, K O ^a,c   Yagita, Hideo ^a,c  

^a JUNTENDO UNIVERSITY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; MEMBRANE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; MOUSE; NEUTROPHIL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNITY, CELLULAR; MEMBRANE GLYCOPROTEINS; MICE; NEOPLASMS, EXPERIMENTAL;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0031042972     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0297-165     Document Type: Article

References (13)

1. Havell, E.A., Fiers, W. & North, R.J. The antitumor function of tumor necrosis factor (TNF). J. Exp. Med. 167, 1067-1085 (1988).
2. Beutler, B. & Cerami, A. The biology of cachectin/TNF: A primary mediator of the host response. Annu. Rev. Immunol. 7, 625-655 (1989).
3. Colombo, M.P. & Forni, G. Cytokine gene transfer in tumor inhibition and tumor therapy; where are we now? Immunol. Today 15, 48-51 (1994).
4. Fearon, E.R. et al. lnterleukin-2 production by tumor cell bypasses T helper function in the generation of an antitumor response. Cell 60, 397-403 (1990).
5. Hock, H. et al. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or Interferon γ. Proc. Natl. Acad. Sci. USA 90, 2774-2778 (1993).
6. + T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene transfection. J. Immunol. 149, 3627-3635 (1992).
7. Maass, G. et al. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: Three consecutive stages may be required for successful tumor vaccination. Proc Natl. Acad. Sci. USA 92, 5540-5544 (1995).
8. Tepper, R.I., Pattengale, P.K. & Leder, P. Murine interleukin-4 displays potent antitumor activity in vivo. Cell 57, 503-512 (1989).
9. Tepper, R.I., Coffman, R.L. St Leder, P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257, 548-551 (1992).
10. Golumbek, P.T. et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713-716 (1991).
11. + T cell-dependent tumor rejection. J. Exp. Med. 174, 1291-1298 (1991).
12. Watanabe, Y. et al. Exogeneous expression of mouse interferon-gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented antitumor immunity. Proc. Natl. Acad. Sci. USA. 86, 9456-9460 (1989).
13. Blankenstein, T. et al. Tumor suppression after tumor cell-targeted tumor necrosis factor α gene transfer. J. Exp. Med. 173, 1047-1052 (1991).